Empress Therapeutics Inc

Compass Therapeutics, Inc., located in Brighton, MA, is focused on developing next-generation antibodies aimed at transformative cancer therapies that enhance patients' lives. By leveraging their understanding of the tumor microenvironment, the company designs product candidates that optimize critical components necessary for an effective antitumor response to cancer. With a robust portfolio of therapeutic candidates that bridge the innate and adaptive immune systems, Compass Therapeutics is advancing its pipeline with exceptional speed and diversity. The company is committed to identifying therapeutic leads that can significantly impact cancer treatment through innovative approaches. Generated from the website

Etiometry is a leading provider of clinical decision support technology, focused on enhancing healthcare delivery through its FDA-cleared platform. By integrating deep physiologic insights and automating clinical pathways, Etiometry enables clinicians to make timely decisions that can improve patient outcomes and reduce costs. The platform empowers high-acuity care teams with advanced data aggregation, risk analytics, and quality improvement tools, allowing for personalized patient care and the standardization of workflows. With a proven track record of reducing ICU readmissions and ventilation times, Etiometry is committed to transforming critical care practices in hospitals. Generated from the website

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins. With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.Generated from the website